Pyxis Oncology (PYXS) Cash & Equivalents (2020 - 2025)

Pyxis Oncology (PYXS) has 6 years of Cash & Equivalents data on file, last reported at $15.4 million in Q4 2025.

• On a quarterly basis, Cash & Equivalents fell 20.8% year-over-year to $15.4 million in Q4 2025; TTM through Dec 2025 was $15.4 million, a 20.8% decrease from a year earlier, with the FY2025 full-year figure at $15.4 million, down 20.8% from the prior year.
• Cash & Equivalents for Q4 2025 stood at $15.4 million, up from $8.9 million in the prior quarter.
• Over the last five years, Cash & Equivalents for PYXS reached as high as $274.7 million in Q4 2021 and fell as low as $8.9 million in Q3 2025.
• Historically, Cash & Equivalents has averaged $88.8 million across 5 years, with a median of $26.9 million in 2023.
• Across the five-year window, Cash & Equivalents jumped 1086.88% in 2021 and slumped 94.61% in 2023, its largest moves.
• Year by year, Cash & Equivalents stood at $274.7 million in 2021, then slumped by 34.74% to $179.3 million in 2022, then slumped by 94.61% to $9.7 million in 2023, then surged by 101.5% to $19.5 million in 2024, then fell by 20.8% to $15.4 million in 2025.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $15.4 million in Q4 2025, $8.9 million in Q3 2025, and $10.7 million in Q2 2025.